Trends Pharmacol Sci.: co-auth.: W.Wahli

Trends Pharmacol Sci. 2023 May 13;S0165-6147(23)00087-1. doi: 10.1016/ 

Striking a gut-liver balance for the antidiabetic effects of metformin

Emma Barroso 1Marta Montori-Grau 1Walter Wahli 2Xavier Palomer 1Manuel Vázquez-Carrera 3


Metformin is the most prescribed drug for the treatment of type 2 diabetes mellitus (T2DM), but its mechanism of action has not yet been completely elucidated. Classically, the liver has been considered the major site of action of metformin. However, over the past few years, advances have unveiled the gut as an additional important target of metformin, which contributes to its glucose-lowering effect through new mechanisms of action. A better understanding of the mechanistic details of metformin action in the gut and the liver and its relevance in patients remains the challenge of present and future research and may impact drug development for the treatment of T2DM. Here, we offer a critical analysis of the current status of metformin-driven multiorgan glucose-lowering effects.